FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3025491372> ?p ?o ?g. }

• W3025491372 endingPage "1253" @default.
• W3025491372 startingPage "1253" @default.
• W3025491372 abstract "Bladder cancer (BCa) is the ninth most commonly diagnosed cancer worldwide. Although there are several well-established molecular and immunological classifications, markers for tumor cells and immune cells that are associated with prognosis are still needed. The chemokine CC motif ligand 2 (CCL2) could be such a marker. We analyzed the expression of CCL2 by immunohistochemistry (IHC) in 168 muscle invasive BCa samples using a tissue microarray. Application of a single cut-off for the staining status of tumor cells (TCs; positive vs. negative) and immune cells (ICs; ≤6% of ICs vs. >6% of ICs) revealed 57 cases (33.9%) and 70 cases (41.7%) with CCL2-positive TCs or ICs, respectively. IHC results were correlated with clinicopathological and survival data. Positive CCL2 staining in TCs was associated with shorter overall survival (OS), disease-specific survival (DSS), and relapse-free survival (RFS) (p = 0.004, p = 0.036, and p = 0.047; log rank test) and appeared to be an independent prognostic factor for OS (RR = 1.70; p = 0.007; multivariate Cox’s regression analysis). In contrast, positive CCL2 staining in the ICs was associated with longer OS, DSS, and RFS (p = 0.032, p = 0.001, and p = 0.001; log rank test) and appeared to be an independent prognostic factor for DSS (RR = 1.77; p = 0.031; multivariate Cox’s regression analysis). Most interestingly, after separating the patients according to their lymph node status (N0 vs. N1+2), CCL2 staining in the ICs was differentially associated with prognosis. In the N0 group, CCL2 positivity in the ICs was a positive independent prognostic factor for OS (RR = 1.99; p = 0.014), DSS (RR = 3.17; p = 0.002), and RFS (RR = 3.10; p = 0.002), whereas in the N1+2 group, CCL2 positivity was a negative independent factor for OS (RR = 3.44; p = 0.019)) and RFS (RR = 4.47; p = 0.010; all multivariate Cox’s regression analyses). In summary, CCL2 positivity in TCs is a negative prognostic factor for OS, and CCL2 can mark ICs that are differentially associated with prognosis depending on the nodal stage of BCa patients. Therefore, CCL2 staining of TCs and ICs is suggested as a prognostic biomarker for BCa patients." @default.
• W3025491372 created "2020-05-21" @default.
• W3025491372 creator A5000515613 @default.
• W3025491372 creator A5016256104 @default.
• W3025491372 creator A5035169110 @default.
• W3025491372 creator A5043291150 @default.
• W3025491372 creator A5044131715 @default.
• W3025491372 creator A5049585448 @default.
• W3025491372 creator A5051550342 @default.
• W3025491372 creator A5066549610 @default.
• W3025491372 creator A5068189118 @default.
• W3025491372 creator A5073600617 @default.
• W3025491372 creator A5073940197 @default.
• W3025491372 creator A5076204719 @default.
• W3025491372 creator A5079268649 @default.
• W3025491372 creator A5086028372 @default.
• W3025491372 creator A5086220621 @default.
• W3025491372 date "2020-05-15" @default.
• W3025491372 modified "2023-10-16" @default.
• W3025491372 title "CCL2 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Shows Divergent Prognostic Potential for Bladder Cancer Patients Depending on Lymph Node Stage" @default.
• W3025491372 cites W1705518899 @default.
• W3025491372 cites W1757407923 @default.
• W3025491372 cites W1963904011 @default.
• W3025491372 cites W1990979240 @default.
• W3025491372 cites W2026993656 @default.
• W3025491372 cites W2030895930 @default.
• W3025491372 cites W2033775272 @default.
• W3025491372 cites W2051317975 @default.
• W3025491372 cites W2066255007 @default.
• W3025491372 cites W2067964015 @default.
• W3025491372 cites W2074244187 @default.
• W3025491372 cites W2093773243 @default.
• W3025491372 cites W2094765963 @default.
• W3025491372 cites W2100153750 @default.
• W3025491372 cites W2106481211 @default.
• W3025491372 cites W2113806836 @default.
• W3025491372 cites W2124614719 @default.
• W3025491372 cites W2135093967 @default.
• W3025491372 cites W2144192318 @default.
• W3025491372 cites W2156064021 @default.
• W3025491372 cites W2336021222 @default.
• W3025491372 cites W2473162054 @default.
• W3025491372 cites W2509266256 @default.
• W3025491372 cites W2527362689 @default.
• W3025491372 cites W2529302828 @default.
• W3025491372 cites W2535009445 @default.
• W3025491372 cites W2586940338 @default.
• W3025491372 cites W2604535399 @default.
• W3025491372 cites W2744685612 @default.
• W3025491372 cites W2744758186 @default.
• W3025491372 cites W2763670669 @default.
• W3025491372 cites W2786512781 @default.
• W3025491372 cites W2792856868 @default.
• W3025491372 cites W2890512043 @default.
• W3025491372 cites W2890715893 @default.
• W3025491372 cites W2891337769 @default.
• W3025491372 cites W2896838078 @default.
• W3025491372 cites W2899131040 @default.
• W3025491372 cites W2908453839 @default.
• W3025491372 cites W2909566946 @default.
• W3025491372 cites W2913857335 @default.
• W3025491372 cites W2940349477 @default.
• W3025491372 cites W2957073922 @default.
• W3025491372 cites W2973979210 @default.
• W3025491372 cites W2975497362 @default.
• W3025491372 cites W2979927617 @default.
• W3025491372 cites W2985764787 @default.
• W3025491372 cites W2990342961 @default.
• W3025491372 cites W2997794888 @default.
• W3025491372 cites W3002395559 @default.
• W3025491372 cites W3007384438 @default.
• W3025491372 cites W312871158 @default.
• W3025491372 cites W4211053712 @default.
• W3025491372 doi "https://doi.org/10.3390/cancers12051253" @default.
• W3025491372 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7281525" @default.
• W3025491372 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32429318" @default.
• W3025491372 hasPublicationYear "2020" @default.
• W3025491372 type Work @default.
• W3025491372 sameAs 3025491372 @default.
• W3025491372 citedByCount "17" @default.
• W3025491372 countsByYear W30254913722020 @default.
• W3025491372 countsByYear W30254913722021 @default.
• W3025491372 countsByYear W30254913722022 @default.
• W3025491372 countsByYear W30254913722023 @default.
• W3025491372 crossrefType "journal-article" @default.
• W3025491372 hasAuthorship W3025491372A5000515613 @default.
• W3025491372 hasAuthorship W3025491372A5016256104 @default.
• W3025491372 hasAuthorship W3025491372A5035169110 @default.
• W3025491372 hasAuthorship W3025491372A5043291150 @default.
• W3025491372 hasAuthorship W3025491372A5044131715 @default.
• W3025491372 hasAuthorship W3025491372A5049585448 @default.
• W3025491372 hasAuthorship W3025491372A5051550342 @default.
• W3025491372 hasAuthorship W3025491372A5066549610 @default.
• W3025491372 hasAuthorship W3025491372A5068189118 @default.
• W3025491372 hasAuthorship W3025491372A5073600617 @default.
• W3025491372 hasAuthorship W3025491372A5073940197 @default.
• W3025491372 hasAuthorship W3025491372A5076204719 @default.
• W3025491372 hasAuthorship W3025491372A5079268649 @default.

• next